EVVY, a vaginal health care company, improves the diagnosis and treatment of bacterial vaginosis, revealed a recent study evaluated by peers. Bacterial vaginosis is a major reason why women are looking for care and can cause pain and discomfort in the vagina.
EVVY, based in New York, is a direct company for consumers. Its vaginal microbiome test at home, from $ 129, checks bacteria and mushrooms (or microbes) in people’s vagins. After passing the test, people receive a report that explains the microbes found in the vagina and the health problems linked to these microbes, such as bacterial vaginosis. Based on the results, consumers receive a personalized treatment plan and an individual virtual session with a coach.
The study, published in Microorganisms Journal, estimated 1,159 patients with bacterial vaginosis. All EVVY’s care has been provided completely remotely, including tests, prescription processing and health coaching. The study revealed that 75.5% of patients reported relief from the symptoms to four weeks using EVVY, while 24.5% have not reported any change or aggravation of symptoms.
In addition, at an average follow -up of 4.4 months, only 30% experienced a recurrence of bacterial vaginosis, against 50% with traditional care. Patients have also seen a reduction in bacterial bacteria associated with vaginosis, such as Gardnerella and Prévotella.
“Vaginal discomfort is a major reason why women are looking for health advice, and traditional care leave women more likely to be poorly diagnosed than properly diagnosed, and more likely to reproduce their infections than to improve,” said Dr. Kate McClean, chief of Evvy, in an email. “This study is the first to demonstrate that personalized and microbiome care can significantly improve recurrence rates and restore microbiome. It validates that precision medicine – fueled by deeper data and proactive support for patients – can radically improve vaginal health results. ”
Currently, more than a third of counties in the United States do not have an Obgyn, and those who often face long waiting times for meetings. EVVY thinks that its home platform could improve this care gap for patients.
McClean added that this study is “just the start” for the company. He currently manages another study on his ability to predict the results of fertility. EVVY launched its offer of fertility information in March, which offers a test that measures protective bacteria associated with improving fertility. It also provides a score of diversity of microbiomas, because a greater diversity of the microbiome is linked to a worst in vitro fertilization and the results of pregnancy. Finally, it tests “fertility disruptors” or the bacteria levels associated with negative results on fertility.
EVVY also hopes to develop in other areas of women’s health in the future, including premature births and gynecological cancers, said McClean.
There are also other vaginal microbiome test companies, including Juno Bio. This company also offers home tests and access to individual coaching.
Photo: Drazen Zigic, Getty Images
